65,437 trials
Multiple Sclerosis
Primary: Change in the Number of Enhancing Leptomeningeal Foci on 1 Year Follow up Compared to Baseline in MS Patients Treated With Ocrelizumab. — 0.07 number of enhancing foci
Diabetes Mellitus Type 2
Primary: Number of Participants With Treatment Emergent Treatment-Related Adverse Events — 5; 2; 6; 6 Participants
Psychosis
Primary: Change in Generalized Anxiety Disorder-7 Pre/Post Test at Week 5 — 4.68; 6.28; 3.96; 7.38 units on a scale — p=0.003
Schizophrenia · Depression · Medical Disorders
Primary: Changed Score on SF-12 Pain Items From Baseline to 6 Months and 12 Months — -.16; .11; .19; -.18 Changed mean z-score — p=.073
Peripheral Artery Disease
Primary: Number of Participants With Target Vessel Patency at 24 Months Post-procedure — 88; 45 Participants
Gastric Adenocarcinoma · GastroEsophageal Cancer
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 40 percent of participants
Lung Cancer Stage III · Lung Cancer Stage IV
Primary: Confidence in Behavior as Measured by the Cancer Behavior Inventory — 80.89; 85.92; 93.23 score on a scale
Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose Limiting-Toxicities (DLTs) After SC Administration — 0; 1; 1; 0 Participants
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -0.6; -7.2; -3.9; -6.7 occasions
Diabetes Mellitus, Type 2
Primary: Change in Glycated Hemoglobin — 1.4; 0.9; 1.1 "Percentage of glycated hemoglobin"
Healthy Volunteers
Primary: Incidence of Treatment-Emergent Adverse Events (TEAEs) — 3; 3; 2 Participants
Newly Diagnosed AML With FLT3 Activating Mutations
Primary: Clinical Response to Crenolanib With Standard Induction Chemotherapy — 26; 12; 38; 22 Participants
Recurrent Kaposi Sarcoma · Skin Kaposi Sarcoma
Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…
Polycystic Ovary Syndrome
Primary: Serum Testosterone — 2.54; 2.54; 2.39; 2.47 nmol/L
Hepatic Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Soticlestat — 3230; 3666; 1435; 1705 nanogram per milliliter (ng/mL)